TITLE

Studies in progressive MS

PUB. DATE
June 2007
SOURCE
Inside MS;Jun/Jul2007, Vol. 25 Issue 3, p20
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on several clinical trials of experimental drugs for the treatment of multiple sclerosis (MS). The experimental drugs that are being studied are for the relapsing forms of MS. These drugs include the ABT-874 monoclonal antibody, cyclophosphamide versus methylprednisolone and Oral Fampridine-SR among others. The medical benefits offered by the drugs are mentioned.
ACCESSION #
25375649

 

Related Articles

  • Happening Now. Sullivan, Gary // Inside MS;Jun/Jul2007, Vol. 25 Issue 3, p16 

    The article focuses on several clinical trials of drugs for multiple sclerosis (MS). Experimental drugs for MS are being developed and tested. Some proven drugs such as Avonex and Copaxone are being combined to test their efficacy. The role of monoclonal antibodies in the treatment of MS are...

  • Alemtuzumab als neue Therapieoption der Multiplen Sklerose. Warnke, C.; Kieseier, B.C.; Zettl, U.; Hartung, H-P. // Nervenarzt;Apr2009, Vol. 80 Issue 4, p468 

    Monoclonal antibodies are of growing interest as treatment options for immune-mediated diseases in neurology. As our knowledge of immunological principals increases, we learn to modulate specifically mechanisms of pathogenesis by the use of monoclonal antibodies. It is clearly desirable to...

  • Ustekinumab & MACE: New monoclonal antibody investigated for cardiovascular safety signal. Martin, George // Dermatology Times;May2011, Vol. 32 Issue 5, p18 

    The article offers updates on the clinical trials for cardiovascular safety of using ustekinumab, a drug used to treat psoriasis from Centocor Ortho Biotech Inc. According to ustekinumab principal investigator Craig Leonardi, major adverse cardiovascular events (MACE) occurred on patients taking...

  • Biogen Idec/Genentech: Promising phase II data for rituximab in MS.  // PharmaWatch: Monthly Review;Jun2007, Vol. 6 Issue 6, p39 

    The article reports that the phase II study for ritumixab has found that it is superior that placebo in preventing brain lesions and reducing relapses in multiple sclerosis (MS). The positive result of the phase II study is stated to be good news for Biogen Idec, which hopes to maintain its...

  • Emerging Therapies in Relapsing-Remitting Multiple Sclerosis. Marriott, James J.; O'Connor, Paul W. // Reviews on Recent Clinical Trials;Sep2010, Vol. 5 Issue 3, p179 

    Disease modifying therapy (DMT) first became available for relapsing-remitting multiple sclerosis (RRMS) fifteen years ago with the development of the moderately effective injectable agents interferon (IFN)-? and glatiramer acetate (GA). The subsequent licensure of mitoxantrone (MX) and...

  • A versus B versus C versus no treatment: A longed-for study offers cloudy results.  // Inside MS;Winter2000, Vol. 18 Issue 1, p42 

    Presents information on a clinical trial comparing Avonex, Betaseron, Copaxone and no treatment at all in people with relapsing-remitting multiple sclerosis. Effectiveness of the drugs on test; Beneficial effects of the drugs.

  • Case history: Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Steinman, Lawrence // Nature Reviews Drug Discovery;Jun2005, Vol. 4 Issue 6, p510 

    Immunologists have long hypothesized that particular 'molecular addresses' govern lymphocyte entry to a given organ. In 1992,α4β1 integrin was identified as the key molecule involved in homing to inflamed regions of the brain. An antibody toα4β1integrin blocked paralysis in an animal...

  • The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade. Kremer, David; Förster, Moritz; Schichel, Tanja; Göttle, Peter; Hartung, Hans-Peter; Perron, Hervé; Küry, Patrick // Multiple Sclerosis Journal;Aug2015, Vol. 21 Issue 9, p1200 

    Background: The envelope protein (ENV) of the human endogenous retrovirus type W is implicated in inflammatory reactions in multiple sclerosis (MS) but also interferes with oligodendroglial maturation. A neutralizing antibody GNbAC1 has been developed and successfully been tested in clinical...

  • CLINIC ROUNDUP.  // BioWorld Today;12/3/2007, Vol. 18 Issue 233, p5 

    This section offers news briefs about clinical trials. Enrollment was completed by Acorda Therapeutics Inc. in its Phase III trial of Fampridine-SR in multiple sclerosis. Positive results were obtained by Alpharma Inc. from its Phase III trial of ALO-01, an abuse-deterrent, extended-release...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics